Z

Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267

Watchlist Manager
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Watchlist
Price: 8.29 CNY -0.96%
Market Cap: 9.7B CNY
Have any thoughts about
Zhejiang Hisun Pharmaceutical Co Ltd?
Write Note
Zhejiang Hisun Pharmaceutical Co Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

Zhejiang Hisun Pharmaceutical Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Hisun Pharmaceutical Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Hisun Pharmaceutical Co Ltd
SSE:600267
Current Portion of Long-Term Debt
¥768.9m
CAGR 3-Years
18%
CAGR 5-Years
2%
CAGR 10-Years
6%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Current Portion of Long-Term Debt
¥4.2B
CAGR 3-Years
625%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Current Portion of Long-Term Debt
¥27.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
12%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Current Portion of Long-Term Debt
¥36.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Current Portion of Long-Term Debt
¥68.7m
CAGR 3-Years
-58%
CAGR 5-Years
-40%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Current Portion of Long-Term Debt
¥179.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Hisun Pharmaceutical Co Ltd
Glance View

Market Cap
10B CNY
Industry
Pharmaceuticals

Zhejiang Hisun Pharmaceutical Co., Ltd. unfolds its story in the competitive arena of China's booming pharmaceutical industry. Founded in 1956, Hisun has gradually matured from a regional player into a recognized name in global generic and specialty drug manufacturing. The company's core strength lies in its integration across the pharmaceutical supply chain, which allows it to produce active pharmaceutical ingredients (APIs) while also scaling up to final dosage forms. Hisun capitalizes on its robust research and development capabilities, investing heavily in innovation to expand its diverse pharmaceutical product portfolio. Through strategic partnerships and collaborative ventures, such as alliances with leading biotech firms, Hisun not only enhances its technological footprint but fortifies its international presence, poised to address the increasing global demand for affordable healthcare solutions. In the sprawling marketplace, Hisun’s financial model is driven by its synergistic blend of producing generic medications and investing in biopharmaceuticals. The firm enjoys a lucrative revenue stream by tapping into the cost-effective production of APIs, which are integral to numerous medications worldwide. Through vertically integrated operations, the company achieves economies of scale, facilitating competitive pricing. Hisun’s foray into more value-added, complex generics and biosimilars further diversifies its income channels, transforming challenges into opportunities amid stringent global regulatory landscapes. By navigating these complexities, Hisun strengthens its market position, leveraging a balance between solid internal growth and strategic global outreach, thus sustaining its journey within the dynamic panorama of the pharmaceutical sector.

Intrinsic Value
13.13 CNY
Undervaluation 37%
Intrinsic Value
Price
Z
What is Intrinsic Value?

See Also

What is Zhejiang Hisun Pharmaceutical Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
768.9m CNY

Based on the financial report for Sep 30, 2024, Zhejiang Hisun Pharmaceutical Co Ltd's Current Portion of Long-Term Debt amounts to 768.9m CNY.

What is Zhejiang Hisun Pharmaceutical Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
6%

Over the last year, the Current Portion of Long-Term Debt growth was -5%. The average annual Current Portion of Long-Term Debt growth rates for Zhejiang Hisun Pharmaceutical Co Ltd have been 18% over the past three years , 2% over the past five years , and 6% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.